ES2556535T3 - Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida - Google Patents

Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida Download PDF

Info

Publication number
ES2556535T3
ES2556535T3 ES13167176.0T ES13167176T ES2556535T3 ES 2556535 T3 ES2556535 T3 ES 2556535T3 ES 13167176 T ES13167176 T ES 13167176T ES 2556535 T3 ES2556535 T3 ES 2556535T3
Authority
ES
Spain
Prior art keywords
het
treatment
disease
cognitive function
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13167176.0T
Other languages
English (en)
Inventor
Samuel T. Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerecin Inc
Original Assignee
Accera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accera Inc filed Critical Accera Inc
Application granted granted Critical
Publication of ES2556535T3 publication Critical patent/ES2556535T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)

Abstract

Un método para seleccionar un paciente para tratamiento de función cognitiva reducida relacionada con la enfermedad causada por reducción del metabolismo neuronal asociada con la enfermedad de Alzheimer (EA), método que comprende: a. seleccionar un paciente que tiene reducción de la función cognitiva relacionada con la enfermedad causada por reducción del metabolismo neuronal asociada a la enfermedad de Alzheimer (EA); b. determinar en el paciente la presencia de homocigosis para adenina de rs2229765 de Precursor de Receptor de tipo Insulínico (IGF1 R) en una porción relevante mostrada por la SEC ID Nº: 6; y c. seleccionar un paciente que tiene el genotipo específico en (b) para tratamiento, en el que el tratamiento comprende la administración al paciente de al menos un triglicérido de cadena media (MCT) en una cantidad eficaz para el tratamiento o la prevención de la reducción de la función cognitiva relacionada con la enfermedad por metabolismo neuronal reducido asociado a la enfermedad de Alzheimer.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
Sujetos
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
APOE rs448647. No se observaron efectos significativos con este alelo.
rs405509 de APOE. Los sujetos que eran heterocigotos en el sitio rs405509 demostraban un aumento de 3,68 puntos en la puntuación de ADAS-Cog cuando se comparan con el placebo (p = 0,0085). rs769446 de APOE. No se observaron efectos significativos con este alelo.
Tabla 2 Tratamiento por Genotipo
Cambio en ADAS-Cog a Partir de la Medida Inicial el Día 90
Genotipo de Tratamiento* con Anova de 2 vías
Snp
Genotipo N para AC-1202 N para Placebo P-valor
rs449647 de APOE
a 39 38 0,147
Het
17 11 0,14
t
3 3 0,4
rs405509 de APOE
g 11 7 0,48
Het
26 27 0,0085
t
23 18 0,629
rs769446 de APOE
Het 5 6 0,405
t
55 46 0,0951
rs1803274 de BUCHE
a 2 Na
g
40 39 0,541
Het
25 15 0,0133
rs2251101 de IDE
C 9 7 0,079
Het
22 25 0,0068
t
36 24 0,266
rs2229765 de IGF1R
A 5 13 0,00719
G
27 18 0,156
het
34 25 0,826
rs28401726 de IGF1R
C 52 48 0,0578
het
14 5 0,901
G
2 Na
rs16944 de IL1B
C 29 27 0,0145
het
28 17 0,845
T
6 9 0,479
rs1143627 de IL1B
C 6 9 0,479
Genotipo de Tratamiento* con Anova de 2 vías
Snp
Genotipo N para AC-1202 N para Placebo Valor de P
het
28 17 0,845
T
29 27 0,0145
rs11669576 de LDLR8
G 59 51 0,025
het
8 5 0,458
rs688 de LDLR13
C 24 22 0,987
23
het
33 20 0,061
T
7 13 0,061
rs2738447 de LDLR13
A 13 11 0,77
C
18 21 0,037
het
32 22 0,176
rs7259278 de LDLR13
G 44 44 0,0236
het
17 8 0,403
T
2 2 0,974
rs1799898 de LDLR 13
C 40 35 0,045
het
18 15 0,126
T
1 1 0,819
rs662 de PON1
A 28 26 0,12
G
6 7 0,239
het
32 23 0,73
rs2251101 de IDE
c/c 9 7 0,079
otro
58 49 0,0059
fuente del programa de AI: phg Tab 3
imagen21 imagen22 imagen23
ADCS-CGIC y MMSE
Cuando se comparan AC-1202 y Placebo en la población de ITT usando LOCF, AC-1202 no conducía a una diferencia significativa en la distribución de las puntuaciones de ADCS-CGIC en cualquier estudio.
Tabla 2 Tratamiento por Genotipo: Puntuación de ADCS-CGIC el Día 90
Valor de P del Genotipo de Tratamiento* con Anova de 2 vías
Snp
genotipo N para Ketasyn N para Placebo
Apoe4
0 1 29 39 26 31 0,218 0,769
rs449647 de APOE
a het t 39 17 3 38 11 33 0,201 0,604 0,796
rs405509 de APOE
g het t 11 26 23 7 27 18 0,6868 0,5660 0,7090
rs769446 de APOE
het t 5 55 6 46 0,441 0,274
rs1803274 de BUCHE
a g het 2 40 25 39 15 Na 0,356 0,574
rs2251101 de IDE
c het t 9 22 36 7 25 24 0,789 0,569 0,259
rs2229765 de IGF1R
a g het 5 27 34 13 18 25 0,350 0,871 0,585
rs28401726 de IGF1R
c het g 52 14 48 5 2 0,299 0,292 Na
24
rs16944 de IL1B
c het t 29 28 6 27 17 9 0,839 0,492 0,437
rs1143627 de IL1B
c het t 6 28 29 9 17 27 0,437 0,492 0,839
rs11669576 de LDLR8
g het 59 8 51 5 0,538 0,935
rs688 de LDLR13
c het t 24 33 7 22 20 13 0,436 0,662 0,295
rs2738447 de LDLR13
a c het 13 18 32 11 21 22 0,635 0,993 0,147
rs7259278 de LDLR13
g het t 44 17 2 44 8 2 0,288 0,552 1
rs1799898 de LDLR 13
c het t 40 18 1 35 15 1 0,175 0,986 0,321
rs662 de PON1
a g het 28 6 32 26 7 23 0,408 0,975 0,722
rs2251101 de IDE
c/c otro 9 58 7 49 0,494 0,790
fuente del programa de AI: phg Tab 5
imagen24
Se encontraron efectos significativos del tratamiento en el cambio a partir de la Medida Inicial en MMSE en Vehículos de rs405509 de APOE y rs662 de PON1.
Tabla 3 Tratamiento por Genotipo: Cambio en MMSE a partir de la Medida Inicial el Día 90
Valor de P del Genotipo de Tratamiento* con Anova de 2 vías
Snp
genotipo N para Ketasyn N para Placebo
Apoe4
0 1 29 39 26 31 0,369 0,704
rs449647 de APOE
A het T 39 17 3 38 11 33 0,595 0,424 0,277
rs405509 de APOE
G het T 11 26 23 7 27 18 0,929 0,067 0,037
rs769446 de APOE
het T 5 55 6 46 0,504 0,834
rs1803274 de BUCHE
A G het 2 40 25 39 15 Na 0,892 0,413
rs2251101 de IDE
C het T 9 22 36 7 25 24 0,908 0,206 0,111
rs2229765 de IGF1R
A G het 5 27 34 13 18 25 0,125 0,929 0,844
25
rs28401726 de IGF1R
C het G 52 14 48 5 2 Na 0,392 0,254
rs16944 de IL1B
C het T 29 28 6 27 17 9 0,846 0,943 0,879
rs1143627 de IL1B
C het T 6 28 29 9 17 27 0,879 0,943 0,846
rs11669576 de LDLR8
G het 59 8 51 5 0,756 0,762
rs688 de LDLR13
C het T 24 33 7 22 20 13 0,240 0,365 0,468
rs2738447 de LDLR13
A C het 13 18 32 11 21 22 0,709 0,265 0,513
rs7259278 de LDLR13
G het T 44 17 2 44 8 2 1 0,903 0,859
rs1799898 de LDLR 13
C het T 40 18 1 35 15 1 0,322 0,145 0,799
rs662 de PON1
A G het 28 6 32 26 7 23 0,085 0,031 0,287
rs2251101 de IDE
c/c otro 9 58 7 49 0,682 0,909
fuente del programa de AI: phg Tab 4
imagen25
Sucesos Adversos que se Producen Antes y Después de un Cambio en el Protocolo de Dosificación
Durante los primeros varios meses del estudio, parecía que se retiraría el estudio un número relativamente elevado
5 de sujetos debido a sucesos adversos gastrointestinales, en particular, por diarrea y flatulencia. Después de una evaluación de las razones dadas para la interrupción, se recomendó que la medicación del estudio o el placebo se deberían mezclar con una bebida con alto contenido de proteína (Ensure™) para aumentar la tolerabilidad del producto en investigación. Se informó de esta decisión a los sitios clínicos y posteriormente se les proporcionó un amplio suministro de Ensure para distribución a los sujetos del estudio. Aunque no se recogieron datos específicos
10 con respecto a que sujetos se adherían a las instrucciones de mezcla de la nueva medicación, Accera tenía razones para creer que Ensure™ llevó a estar disponible para todos los sujetos que estaban en el estudio en es el punto temporal o se inscribieron después del cambio.
Para evaluar si o no este cambio en las instrucciones en vez de la medicación del estudio parecía a aumentar la
15 tolerabilidad del producto, se realizó un análisis de las interrupciones del sujeto antes y después de realizar el cambio.
Interrupciones Antes del Cambio
20 Diez sujetos [9 de 31 (29,0 %) con Tratamiento y 1 de 27 (3,4 %) de placebo] interrumpieron el estudio. durante este periodo de tiempo, algunos sucesos dentro del sistema gastrointestinal fueron la causa principal de retirada del estudio. Dentro del sistema GI, 7 de 31 (22,6 %) sujetos con Tratamiento y 1 de 27 (3,4 %) sujetos con placebo interrumpieron el estudio debido a uno o más sucesos adversos.
25 Interrupciones Después del Cambio
Después del cambio de las instrucciones de mezcla de la medicación, la incidencia global de sucesos adversos que conducían a la interrupción del estudio disminuyó ligeramente en el grupo con el Tratamiento de un 29,0 % a un 21,9 %. De forma más notable, la incidencia de sucesos gastrointestinales que causaban la retirada del estudio en el
30 grupo con el Tratamiento disminuyó de un 22,6 % a un 12,5 %.
26

Claims (1)

  1. imagen1
    imagen2
ES13167176.0T 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida Active ES2556535T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95307407P 2007-07-31 2007-07-31
US953074P 2007-07-31

Publications (1)

Publication Number Publication Date
ES2556535T3 true ES2556535T3 (es) 2016-01-18

Family

ID=40305284

Family Applications (6)

Application Number Title Priority Date Filing Date
ES13167177.8T Active ES2608286T3 (es) 2007-07-31 2008-07-31 Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167176.0T Active ES2556535T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES08796988.7T Active ES2608846T3 (es) 2007-07-31 2008-07-31 Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167174.5T Active ES2556537T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167175.2T Active ES2556536T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167178.6T Active ES2556534T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13167177.8T Active ES2608286T3 (es) 2007-07-31 2008-07-31 Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES08796988.7T Active ES2608846T3 (es) 2007-07-31 2008-07-31 Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167174.5T Active ES2556537T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167175.2T Active ES2556536T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
ES13167178.6T Active ES2556534T3 (es) 2007-07-31 2008-07-31 Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida

Country Status (10)

Country Link
US (2) US9175345B2 (es)
EP (6) EP2650378B1 (es)
JP (1) JP5819065B2 (es)
KR (1) KR101335021B1 (es)
CN (1) CN101809443B (es)
AU (1) AU2008282130B2 (es)
CA (3) CA3078084C (es)
ES (6) ES2608286T3 (es)
PT (6) PT2650382E (es)
WO (1) WO2009018478A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
PT2650382E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
KR101734152B1 (ko) 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
WO2011082111A1 (en) * 2009-12-30 2011-07-07 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
AU2013358951C1 (en) 2012-12-13 2019-06-27 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
US9833430B2 (en) 2013-11-14 2017-12-05 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
CN104305192B (zh) * 2014-10-23 2016-05-04 贡岳松 改善老年痴呆症患者记忆的功能性食品及其制备方法
JP7399465B2 (ja) * 2017-05-15 2023-12-18 インフォメディテック・カンパニー，リミテッド アルツハイマー病の危険性と関連するａｐｏｅプロモーターの一塩基多型およびその使用
CN109480284A (zh) * 2018-12-05 2019-03-19 上海欣海生物科技有限公司 一种生酮食品及其制备方法
US20220125925A1 (en) * 2019-03-04 2022-04-28 Cerecin Inc. Medium chain triglyceride formulations with improved bioavailability and methods related thereto
CN112903885B (zh) * 2019-12-03 2022-05-06 中国科学院大连化学物理研究所 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒
CN112226504B (zh) * 2020-10-21 2021-06-08 北京市劳动保护科学研究所 BuChE基因SNP位点的用途及新烟碱农药接触人群高TG血症易感性分析检测试剂盒
JP7414693B2 (ja) 2020-11-09 2024-01-16 三協立山株式会社 建具

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766146A (en) 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766145A (en) 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
US4112123A (en) 1976-07-21 1978-09-05 Beatrice Foods Co. Nutritionally balanced single food composition and method of production
US4346107A (en) 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
FR2490631A1 (fr) 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
US4687782A (en) 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
JPH0829055B2 (ja) 1986-09-12 1996-03-27 大塚製薬株式会社 食品組成物
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
SE8803141L (sv) 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
JP2654812B2 (ja) 1988-09-24 1997-09-17 コニカ株式会社 湾曲を防止したハロゲン化銀写真感光材料
US5118670A (en) 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE3843238C1 (es) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
IT1240775B (it) 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
JP2735927B2 (ja) 1990-03-26 1998-04-02 鐘紡株式会社 密封容器入り中性飲料
WO1991015963A1 (en) 1990-04-26 1991-10-31 The Procter & Gamble Company Shortening compositions containing polyol fatty acid polyesters
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5175190A (en) 1991-02-15 1992-12-29 The University Of British Columbia Medium chain fatty acids of C8-10 for the treatment of skin lesions
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
GB9113484D0 (en) 1991-06-21 1991-08-07 Unilever Plc Cosmetic composition
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
EP0587377A3 (en) 1992-09-10 1994-09-21 Lilly Co Eli Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease
NZ257215A (en) 1992-10-13 1996-12-20 Univ Duke Diagnosis or prognosis of alzheimers using the presence of apolipoprotein e type 4 as an indicator and apolipoprotein e isoform specific antibodies
US5494794A (en) 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
JPH0725760A (ja) 1993-07-09 1995-01-27 Green Cross Corp:The アルツハイマー病予防治療剤
US5420335A (en) 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
WO1995009144A1 (en) 1993-09-30 1995-04-06 Eastman Chemical Company Nutritive water soluble glycerol esters of hydroxy butyric acid
US5438042B1 (en) 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5691325A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US7049078B2 (en) 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
GB9408465D0 (en) 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
DE69535104T2 (de) 1994-11-08 2007-02-08 Avicena Group, Inc., Cambridge Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
ATE218583T1 (de) 1995-03-14 2002-06-15 Praecis Pharm Inc Verbindungen mit aggregations-modulierenden wirkung auf das amyloid protein
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6022683A (en) 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JPH097785A (ja) 1995-06-26 1997-01-10 Mitsubishi Electric Corp 放電灯点灯装置
AU6858696A (en) 1995-08-24 1997-03-19 Advanced Nutritionals Corporation Carbohydrate and medium chain triglyceride gel as an energy supplement
US5635199A (en) 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
DE19609476A1 (de) 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
IT1284650B1 (it) 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
KR980008239A (ko) 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
DE69838789T2 (de) 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
AU749638B2 (en) 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
JPH1198952A (ja) 1997-09-29 1999-04-13 Fuji Oil Co Ltd 油脂含有食品及びその製造方法
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US20040058873A1 (en) 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU759467B2 (en) 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AU4573799A (en) 1998-06-19 2000-01-05 Beth Israel Deaconess Medical Center Dietary supplement for individuals under stress
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
ATE283056T1 (de) 1998-07-22 2004-12-15 Metabolix Inc Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
CN1313895A (zh) 1998-09-14 2001-09-19 泛太平洋制药公司 蜂毒蛋白的有用特性和编码这种蜂毒蛋白的基因
NZ509739A (en) * 1998-09-15 2003-10-31 Btg Int Ltd A cyclic ester of (R)-3-hydroxybutyrate useful for increasing cardiac efficiency
GB9908202D0 (en) 1999-04-12 1999-06-02 Unilever Plc Cosmetic compositions
US20070179197A1 (en) 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60138019D1 (de) 2000-05-01 2009-04-30 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
DE20012857U1 (de) 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gm Diätetisches Lebensmittel zum Fettabbau
US6667397B2 (en) 2000-08-25 2003-12-23 Eastman Chemical Company Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom
GB2368011A (en) 2000-10-17 2002-04-24 Unilever Plc Fatty acid esters of maltose and uses thereof
US20020103139A1 (en) 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
KR100479741B1 (ko) 2000-12-30 2005-03-30 주식회사 엘지생활건강 글루코오스 아실화 유도체 또는 수크로오스 아실화유도체를 함유하는 피부미백제
JP2004534050A (ja) 2001-06-07 2004-11-11 エーザイ株式会社 細胞ストレスに関連する疾病及び状態を予防及び治療する方法
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU2002336759A1 (en) 2001-09-21 2003-04-14 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
AU2002364945A1 (en) * 2001-10-25 2003-07-09 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
GB0128510D0 (en) 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CN1681941A (zh) * 2002-08-07 2005-10-12 诺瓦提斯公司 基于ApoE基因型治疗痴呆的方法
US7320806B2 (en) 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
US6884454B2 (en) 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2006519843A (ja) 2003-03-06 2006-08-31 アクセラ・インコーポレーテッド 新規化学物質及び代謝異常の治療におけるそれらの使用法
WO2004108740A2 (en) 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20050013884A1 (en) 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
SI1750716T1 (sl) 2004-05-30 2009-06-30 Sloan Kettering Inst Cancer Zdravljenje t-celiäśnega limfoma z uporabo 10-propargil-10-deazaaminopterina
JP2006287138A (ja) 2005-04-05 2006-10-19 Mitsubishi Materials Corp 受動部品形成用積層フィルム及びシート型受動部品並びにその製造方法
US20060252775A1 (en) 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
CA2632550C (en) * 2005-12-15 2017-07-25 Nestec S.A. Medium chain triglycerides for preserving cognitive function
US20070173602A1 (en) 2006-01-25 2007-07-26 Brinkman Larry F Encapsulated Michael addition catalyst
HUE040002T2 (hu) 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
JP2008104359A (ja) 2006-10-23 2008-05-08 Dainippon Ink & Chem Inc 酵素固定用担体、固定化酵素および酵素固定用担体の製造方法
PT2650382E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida

Also Published As

Publication number Publication date
ES2556534T3 (es) 2016-01-18
WO2009018478A2 (en) 2009-02-05
EP2650378B1 (en) 2015-09-16
EP2179284B1 (en) 2016-09-28
EP2650381B1 (en) 2016-09-21
PT2650382E (pt) 2016-01-14
EP2650382B1 (en) 2015-09-16
CN101809443A (zh) 2010-08-18
KR20100044871A (ko) 2010-04-30
JP2010535037A (ja) 2010-11-18
EP2650381A1 (en) 2013-10-16
CA2853992A1 (en) 2009-02-05
AU2008282130A1 (en) 2009-02-05
EP2650382B9 (en) 2016-04-13
CA2694925C (en) 2014-07-15
CA3078084C (en) 2023-08-15
US9175345B2 (en) 2015-11-03
PT2650381T (pt) 2016-12-29
ES2608286T3 (es) 2017-04-07
EP2179284A4 (en) 2010-09-01
PT2650378E (pt) 2016-01-14
EP2650378A1 (en) 2013-10-16
PT2650379E (pt) 2016-01-13
EP2650379B1 (en) 2015-09-16
CA3078084A1 (en) 2009-02-05
JP5819065B2 (ja) 2015-11-18
US10105338B2 (en) 2018-10-23
CA2853992C (en) 2020-06-23
EP2650380B1 (en) 2015-09-16
ES2556534T9 (es) 2016-07-06
CA2694925A1 (en) 2009-02-05
EP2650379A1 (en) 2013-10-16
AU2008282130B2 (en) 2014-08-21
ES2608846T3 (es) 2017-04-17
CN101809443B (zh) 2013-11-27
US20160030376A1 (en) 2016-02-04
EP2650380A1 (en) 2013-10-16
EP2650382A1 (en) 2013-10-16
ES2556537T3 (es) 2016-01-18
PT2179284T (pt) 2016-12-30
US20110243885A1 (en) 2011-10-06
WO2009018478A3 (en) 2009-03-12
PT2650380E (pt) 2016-01-14
EP2179284A2 (en) 2010-04-28
ES2556536T3 (es) 2016-01-18
KR101335021B1 (ko) 2013-12-12

Similar Documents

Publication Publication Date Title
ES2556535T3 (es) Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
JP7175371B2 (ja) スタチンの応答および心血管疾患に関連する遺伝子多型、その検出方法ならびに使用
US20170343561A1 (en) Diagnostic and therapeutic methods and products related to anxiety disorders
Chen et al. Synaptic proteins and receptors defects in autism spectrum disorders
Burnside et al. Microdeletion/microduplication of proximal 15q11. 2 between BP1 and BP2: a susceptibility region for neurological dysfunction including developmental and language delay
Hohoff et al. Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality
Choi et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder
ES2456919T3 (es) Nuevos polimorfismos en ABCB1 asociados con una falta de respuesta clínica a medicamentos
Karayiorgou et al. The molecular genetics of the 22q11-associated schizophrenia
Jardanhazi-Kurutz et al. Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice
Tsai et al. Effects of BDNF polymorphisms on antidepressant action
Xu et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population.
CA2854779A1 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
Vysokanov et al. mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons
Haerian et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy
Glazner et al. Strain specific differences in memory and neuropathology in a mouse model of Alzheimer's disease
Lennertz et al. 5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option
Grady et al. Sequence variants of the DRD4 gene in autism: further evidence that rare DRD4 7R haplotypes are ADHD specific
Crisafulli et al. Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder
Sheikh et al. Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers
O'Tuathaigh et al. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
Mitra et al. Association of circulating BDNF levels with BDNF rs6265 polymorphism in schizophrenia
Kim et al. Association study of polymorphisms between DISC1 and schizophrenia in a Korean population
Stepanov et al. Analysis of association of genetic markers in the LUZP2 and FBXO40 genes with the normal variability in cognitive performance in the elderly
Lin et al. MET and AKT genetic influence on facial emotion perception